What does it take to build a stronger, more resilient Europe? Secure access to affordable medicines made in Europe is emerging as a cornerstone of economic competitiveness, critical infrastructure resilience, and defense readiness. Marking 20 years of biosimilars in Europe, this session brings together leaders from health, industry, and policy and explores how Europe can transform resilience into a strategic advantage and strengthen its capacity to thrive in an uncertain world.